Stock Events

Stock Events

Abbvie 

0
33361
+$0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

25OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
2.27
2.5
2.72
2.95
Expected EPS
2.952384
Actual EPS
N/A

Financials

19.55%Profit Margin
Profitable
2017
2018
2019
2020
2021
2022
73.18BRevenue
14.31BNet Income

Analyst Ratings

282.80Average Price Target
The highest estimate is 300.00.
From 15 ratings within the last 6 months. This is not an investment recommendation.
Buy
87%
Hold
13%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson competes with AbbVie in the pharmaceutical sector, particularly in immunology and oncology.
Pfizer
PFE
Mkt Cap162.16B
Pfizer competes across several therapeutic areas including immunology and oncology, similar to AbbVie's portfolio.
Merck
MRK
Mkt Cap370.89B
Merck is a key competitor in the pharmaceutical industry, especially in the oncology market where both companies have significant investments.
GSK
GSK
Mkt Cap99.96B
GlaxoSmithKline competes with AbbVie in the pharmaceutical and healthcare sector, with overlapping interests in immunology.
Novartis
NVS
Mkt Cap304.1B
Novartis competes with AbbVie in multiple areas including immunology and neuroscience.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb competes in the biopharmaceutical sector, particularly in oncology and cardiovascular diseases, areas where AbbVie is also active.
AMGEN
AMGN
Mkt Cap236.38B
Amgen competes with AbbVie in the biotech sector, particularly in treatments for inflammatory diseases.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG competes with AbbVie in the oncology and immunology sectors, with a strong focus on biopharmaceuticals.
Sanofi
SNY
Mkt Cap106.01B
Sanofi competes with AbbVie in areas such as immunology, with both companies developing treatments for various autoimmune diseases.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca competes with AbbVie, particularly in the oncology sector, where both companies are seeking to expand their portfolios.

About

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Show more...
CEO
Robert A. Michael
Employees
57000
Country
United States
ISIN
XS2055646918

Listings

XNYS
US
ABBV
F
DE
4AB.F
STU
DE
4AB.STU
BK
TH
ABBV19.BK

0 Comments

Share your thoughts

FAQ

What is Abbvie stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange Abbvie stocks are traded under the ticker ABBV27.
What is Abbvie revenue for the last year?▼
Abbvie revenue for the last year amounts to 73.18B USD.
What is Abbvie net income for the last year?▼
ABBV27 net income for the last year is 14.31B USD.
How many employees does Abbvie have?▼
As of September 08, 2026, the company has 57,000 employees.
In which sector is Abbvie located?▼
Abbvie operates in the Health & Wellness sector.
When did Abbvie complete a stock split?▼
Abbvie has not had any recent stock splits.
Where is Abbvie headquartered?▼
Abbvie is headquartered in NORTH CHICAGO, United States.